A detailed history of Bank Of America Corp transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Bank Of America Corp holds 314,906 shares of APLT stock, worth $3.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
314,906
Previous 229,862 37.0%
Holding current value
$3.03 Million
Previous $1.07 Million 149.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.35 - $8.5 $369,941 - $722,874
85,044 Added 37.0%
314,906 $2.68 Million
Q2 2024

Aug 14, 2024

BUY
$4.04 - $6.37 $785,040 - $1.24 Million
194,317 Added 546.68%
229,862 $1.07 Million
Q1 2024

May 15, 2024

SELL
$2.25 - $7.4 $20,443 - $67,236
-9,086 Reduced 20.36%
35,545 $241,000
Q4 2023

Feb 14, 2024

BUY
$1.84 - $3.35 $82,119 - $149,510
44,630 Added 4463000.0%
44,631 $149,000
Q2 2023

Aug 14, 2023

SELL
$0.77 - $1.8 $280 - $655
-364 Reduced 99.73%
1 $0
Q1 2023

May 12, 2023

BUY
$0.75 - $1.21 $177 - $285
236 Added 182.95%
365 $0
Q4 2022

Feb 10, 2023

SELL
$0.54 - $1.12 $177 - $368
-329 Reduced 71.83%
129 $0
Q3 2022

Nov 14, 2022

SELL
$0.86 - $1.55 $3,383 - $6,097
-3,934 Reduced 89.57%
458 $0
Q2 2022

Aug 12, 2022

SELL
$0.76 - $2.64 $12,004 - $41,701
-15,796 Reduced 78.24%
4,392 $4,000
Q1 2022

May 16, 2022

SELL
$1.48 - $6.22 $23,447 - $98,543
-15,843 Reduced 43.97%
20,188 $43,000
Q4 2021

Feb 08, 2022

BUY
$8.77 - $18.29 $188,449 - $393,015
21,488 Added 147.75%
36,031 $322,000
Q3 2021

Nov 15, 2021

BUY
$13.54 - $22.06 $22,557 - $36,751
1,666 Added 12.94%
14,543 $242,000
Q2 2021

Sep 13, 2021

BUY
$14.05 - $25.04 $180,921 - $322,440
12,877 New
12,877 $268,000

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $462M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.